Testing effectiveness (Phase 2)Study completedNCT03914742
What this trial is testing
BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations
Who this might be right for
IDH1 MutationIDH2 MutationRecurrent Glioblastoma+2 more
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 67